SM
Starfish Medicines at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Starfish Medicines brings 2 presentations to ObesityWeek 2026 in National Harbor. Its sessions present preclinical work on antibody peptide conjugates for obesity. One shows the anti-myostatin-incretin conjugate STAR-306 improving lean mass retention in a DIO model, and another characterizes an anti-GIPR-GLP1/amylin antibody peptide conjugate.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
SM Starfish Medicines | |
Developer of antibody-peptide conjugates, working on anti-myostatin and anti-GIPR candidates for obesity. | Poster Sat Nov 14 7:30pm–8:30pm STAR-306: An Anti-Myostatin-Incretin APC Improves Lean Mass Retention in a Preclinical DIO Model Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Preclinical Characterization of a First-in-Class Anti-GIPR-GLP1/Amylin Antibody Peptide Conjugate Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology |
Find decision makers at Starfish Medicines
Tell us what you sell and we’ll find the people at Starfish Medicines most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction